Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The lancet Respiratory …, 2016 - thelancet.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements, DE Furst… - The Lancet Respiratory …, 2016 - infona.pl
12 months of oral cyclophosphamide has been shown to alter the progression of
scleroderma-related interstitial lung disease when compared with placebo. However, toxicity …
scleroderma-related interstitial lung disease when compared with placebo. However, toxicity …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - experts.umn.edu
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …
[HTML][HTML] Mycophenolate Mofetil versus Oral Cyclophosphamide in Scleroderma-related Interstitial Lung Disease: Scleroderma Lung Study II (SLS-II), a double-blind …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - ncbi.nlm.nih.gov
BACKGROUND Twelve months of oral cyclophosphamide (CYC) has been shown to alter
the progression of scleroderma-related interstitial lung disease (SSc-ILD) when compared to …
the progression of scleroderma-related interstitial lung disease (SSc-ILD) when compared to …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - scholars.northwestern.edu
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …
[引用][C] Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel …
DP Tashkin, MD Roth, PJ Clements, DE Furst… - The Lancet Respiratory …, 2016 - elibrary.ru
SLS II was a randomised, double-blind, parallel group, trial done at 14 US medical centres.
The protocol was approved by a Data and Safety Monitoring Board constituted by the …
The protocol was approved by a Data and Safety Monitoring Board constituted by the …
[引用][C] Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel …
DP Tashkin, MD Roth, PJ Clements, DE Furst… - The Lancet Respiratory …, 2016 - cir.nii.ac.jp
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung
disease (SLS II): a randomised controlled, double-blind, parallel group trial | CiNii Research …
disease (SLS II): a randomised controlled, double-blind, parallel group trial | CiNii Research …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - researchwithrutgers.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - europepmc.org
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …
DP Tashkin, MD Roth, PJ Clements… - The Lancet …, 2016 - pure.johnshopkins.edu
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However …
of scleroderma-related interstitial lung disease when compared with placebo. However …